AbCellera Nears Key Catalyst as Pipeline Candidates Advance

Shares of AbCellera Biologics have been on a tear, climbing nearly 11% on Monday to €3.88 and pushing year-to-date gains past 33%. The stock now sits just shy of its 52-week high, reflecting growing investor conviction that the company is on the cusp of a major transition from a pure-play technology partner to a fully-fledged drug developer.

The catalyst generating all this excitement? The upcoming release of initial clinical data from the company’s first wholly-owned candidate, ABCL635. This antibody targets menopausal symptoms without the use of hormones, and management plans to unveil early Phase 1 results during the first-quarter earnings call in May. A more comprehensive readout from the Phase 2 portion of the study is slated for the third quarter of 2026.

ABCL635 is more than just another pipeline asset — it represents the first clinical candidate to emerge from AbCellera’s proprietary GPCR platform. A successful data readout would validate the entire discovery engine, proving that the company can do more than just identify antibodies for partners. It can bring its own medicines to the clinic.

The company’s financial footing adds to the narrative. With more cash than debt on the balance sheet, AbCellera has the runway to continue advancing ABCL635 and its other internal program, ABCL575, which targets atopic dermatitis. The May earnings report will offer a deeper look at the operational details behind these efforts.

Should investors sell immediately? Or is it worth buying AbCellera Biologics?

Beyond its internal pipeline, AbCellera maintains a network of strategic alliances with pharmaceutical partners across oncology and cardiovascular disease. These collaborations offer milestone payments and ongoing royalty streams, providing a secondary value driver that complements the in-house development work.

Legal overhangs have also been cleared. A patent dispute with Bruker Corporation was resolved via a settlement in December 2025, removing a cloud of uncertainty and protecting the company’s intellectual property.

With the stock trading at €3.83 — just a stone’s throw from its 52-week high — the upcoming quarterly results in May will be a critical test. Investors will be watching closely to see whether AbCellera’s platform can deliver on its clinical promises.